Contractile dysfunction in experimental cardiac allograft rejection: Role of the poly (ADP-ribose) polymerase pathway

Gábor Szabó, Susanne Bährle, Nicole Stumpf, Csaba Szabo, Siegfried Hagl

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Recent studies suggested that the peroxynitrite-poly (ADP-ribose) polymerase (PARP) pathway is activated during acute allograft rejection. We investigated whether PARP inhibition improves transplant function during cardiac rejection. Isogeneic Lewis-to-Lewis and allogeneic Dark Agouti-to-Lewis rat cardiac transplants were studied under treatment with placebo or with the PARP-inhibitor INO-1001 (1 mk/kg/day), Functional, biochemical and histological analysis were performed 3 and 5 days after transplantation. After 3 days, baseline left ventricular pressure-volume relationships did not differ between the groups. However, coronary blood flow (4.3 ± 0.5 vs. 2.2 ± 0.2 vs. 4.1 ± 0.3 ml/min/g, P < 0.05) and contractile response to dobutamine (Δ+dP/dt: 98 ± 11 vs. 57 ± 7 vs. 88 ± 8%, P < 0.05) decreased significantly in the placebo group, which was abolished by INO-1001. Vasodilatory response to acethylcholine was reduced in the placebo group (78 ± 6 vs. 36 ± 9 vs. 72 ± 7%, P < 0.05). After 5 days, baseline systolic and diastolic pressure-volume relationships were impaired (P < 0.05) in the placebo group and the response to dobutamine and to acethylcholine deteriorated further which was abolished by INO-1001. Histology confirmed mild to moderate rejection after 3 days and severe acute rejection after 5 days in the allogeneic groups. Thus, contractile and vasomotor dysfunction occur in a typical time dependent manner during cardiac rejection, which can be reduced by PARP-inhibition.

Original languageEnglish (US)
Pages (from-to)506-513
Number of pages8
JournalTransplant International
Volume19
Issue number6
DOIs
StatePublished - Jun 2006
Externally publishedYes

Fingerprint

Poly(ADP-ribose) Polymerases
Allografts
Placebos
Dobutamine
Blood Pressure
Transplants
Peroxynitrous Acid
Ventricular Pressure
Histology
Transplantation
INO 1001
Therapeutics

Keywords

  • Cardiac function
  • PARP
  • Rat
  • Rejection
  • Transplantation

ASJC Scopus subject areas

  • Transplantation

Cite this

Contractile dysfunction in experimental cardiac allograft rejection : Role of the poly (ADP-ribose) polymerase pathway. / Szabó, Gábor; Bährle, Susanne; Stumpf, Nicole; Szabo, Csaba; Hagl, Siegfried.

In: Transplant International, Vol. 19, No. 6, 06.2006, p. 506-513.

Research output: Contribution to journalArticle

Szabó, Gábor ; Bährle, Susanne ; Stumpf, Nicole ; Szabo, Csaba ; Hagl, Siegfried. / Contractile dysfunction in experimental cardiac allograft rejection : Role of the poly (ADP-ribose) polymerase pathway. In: Transplant International. 2006 ; Vol. 19, No. 6. pp. 506-513.
@article{567e57cce5f24b38aad04cd803f04a41,
title = "Contractile dysfunction in experimental cardiac allograft rejection: Role of the poly (ADP-ribose) polymerase pathway",
abstract = "Recent studies suggested that the peroxynitrite-poly (ADP-ribose) polymerase (PARP) pathway is activated during acute allograft rejection. We investigated whether PARP inhibition improves transplant function during cardiac rejection. Isogeneic Lewis-to-Lewis and allogeneic Dark Agouti-to-Lewis rat cardiac transplants were studied under treatment with placebo or with the PARP-inhibitor INO-1001 (1 mk/kg/day), Functional, biochemical and histological analysis were performed 3 and 5 days after transplantation. After 3 days, baseline left ventricular pressure-volume relationships did not differ between the groups. However, coronary blood flow (4.3 ± 0.5 vs. 2.2 ± 0.2 vs. 4.1 ± 0.3 ml/min/g, P < 0.05) and contractile response to dobutamine (Δ+dP/dt: 98 ± 11 vs. 57 ± 7 vs. 88 ± 8{\%}, P < 0.05) decreased significantly in the placebo group, which was abolished by INO-1001. Vasodilatory response to acethylcholine was reduced in the placebo group (78 ± 6 vs. 36 ± 9 vs. 72 ± 7{\%}, P < 0.05). After 5 days, baseline systolic and diastolic pressure-volume relationships were impaired (P < 0.05) in the placebo group and the response to dobutamine and to acethylcholine deteriorated further which was abolished by INO-1001. Histology confirmed mild to moderate rejection after 3 days and severe acute rejection after 5 days in the allogeneic groups. Thus, contractile and vasomotor dysfunction occur in a typical time dependent manner during cardiac rejection, which can be reduced by PARP-inhibition.",
keywords = "Cardiac function, PARP, Rat, Rejection, Transplantation",
author = "G{\'a}bor Szab{\'o} and Susanne B{\"a}hrle and Nicole Stumpf and Csaba Szabo and Siegfried Hagl",
year = "2006",
month = "6",
doi = "10.1111/j.1432-2277.2005.00262.x",
language = "English (US)",
volume = "19",
pages = "506--513",
journal = "Transplant International",
issn = "0934-0874",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Contractile dysfunction in experimental cardiac allograft rejection

T2 - Role of the poly (ADP-ribose) polymerase pathway

AU - Szabó, Gábor

AU - Bährle, Susanne

AU - Stumpf, Nicole

AU - Szabo, Csaba

AU - Hagl, Siegfried

PY - 2006/6

Y1 - 2006/6

N2 - Recent studies suggested that the peroxynitrite-poly (ADP-ribose) polymerase (PARP) pathway is activated during acute allograft rejection. We investigated whether PARP inhibition improves transplant function during cardiac rejection. Isogeneic Lewis-to-Lewis and allogeneic Dark Agouti-to-Lewis rat cardiac transplants were studied under treatment with placebo or with the PARP-inhibitor INO-1001 (1 mk/kg/day), Functional, biochemical and histological analysis were performed 3 and 5 days after transplantation. After 3 days, baseline left ventricular pressure-volume relationships did not differ between the groups. However, coronary blood flow (4.3 ± 0.5 vs. 2.2 ± 0.2 vs. 4.1 ± 0.3 ml/min/g, P < 0.05) and contractile response to dobutamine (Δ+dP/dt: 98 ± 11 vs. 57 ± 7 vs. 88 ± 8%, P < 0.05) decreased significantly in the placebo group, which was abolished by INO-1001. Vasodilatory response to acethylcholine was reduced in the placebo group (78 ± 6 vs. 36 ± 9 vs. 72 ± 7%, P < 0.05). After 5 days, baseline systolic and diastolic pressure-volume relationships were impaired (P < 0.05) in the placebo group and the response to dobutamine and to acethylcholine deteriorated further which was abolished by INO-1001. Histology confirmed mild to moderate rejection after 3 days and severe acute rejection after 5 days in the allogeneic groups. Thus, contractile and vasomotor dysfunction occur in a typical time dependent manner during cardiac rejection, which can be reduced by PARP-inhibition.

AB - Recent studies suggested that the peroxynitrite-poly (ADP-ribose) polymerase (PARP) pathway is activated during acute allograft rejection. We investigated whether PARP inhibition improves transplant function during cardiac rejection. Isogeneic Lewis-to-Lewis and allogeneic Dark Agouti-to-Lewis rat cardiac transplants were studied under treatment with placebo or with the PARP-inhibitor INO-1001 (1 mk/kg/day), Functional, biochemical and histological analysis were performed 3 and 5 days after transplantation. After 3 days, baseline left ventricular pressure-volume relationships did not differ between the groups. However, coronary blood flow (4.3 ± 0.5 vs. 2.2 ± 0.2 vs. 4.1 ± 0.3 ml/min/g, P < 0.05) and contractile response to dobutamine (Δ+dP/dt: 98 ± 11 vs. 57 ± 7 vs. 88 ± 8%, P < 0.05) decreased significantly in the placebo group, which was abolished by INO-1001. Vasodilatory response to acethylcholine was reduced in the placebo group (78 ± 6 vs. 36 ± 9 vs. 72 ± 7%, P < 0.05). After 5 days, baseline systolic and diastolic pressure-volume relationships were impaired (P < 0.05) in the placebo group and the response to dobutamine and to acethylcholine deteriorated further which was abolished by INO-1001. Histology confirmed mild to moderate rejection after 3 days and severe acute rejection after 5 days in the allogeneic groups. Thus, contractile and vasomotor dysfunction occur in a typical time dependent manner during cardiac rejection, which can be reduced by PARP-inhibition.

KW - Cardiac function

KW - PARP

KW - Rat

KW - Rejection

KW - Transplantation

UR - http://www.scopus.com/inward/record.url?scp=33646685481&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646685481&partnerID=8YFLogxK

U2 - 10.1111/j.1432-2277.2005.00262.x

DO - 10.1111/j.1432-2277.2005.00262.x

M3 - Article

C2 - 16771873

AN - SCOPUS:33646685481

VL - 19

SP - 506

EP - 513

JO - Transplant International

JF - Transplant International

SN - 0934-0874

IS - 6

ER -